Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.

This study found that breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapy experienced more pronounced vertex hair loss and were less responsive to minoxidil treatment compared to those on endocrine monotherapy.

This study found that 49% of female breast cancer patients treated with CDK4/6 inhibitors for at least three months developed alopecia, which significantly impacted their quality of life, with greater alopecia severity leading to worse emotional and functional well-being.

In this study, the researchers found that different CDK4/6 inhibitors used in treating HR+/HER2- advanced breast cancer have varying safety profiles and impacts on patient quality of life.

This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.

This study found that patients, oncologists, and payers prioritize a significant improvement in efficacy to justify the added risks and costs when considering CDK4/6 inhibitors combined with endocrine therapy for early-stage breast cancer.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

In this study, researchers found that pregnant mice exposed to excessive androgen led to thinner ventricular walls and cardiac hypertrophy in offspring, suggesting that prenatal androgen exposure adversely affects cardiac health through reduced cardiomyocyte proliferation.

This study, using modified Delphi panels, provided consensus recommendations for managing alpelisib-induced hyperglycemia and rash, advising prophylactic metformin starting for certain risk groups and the use of nonsedating H1 antihistamines and topical steroids for initial rash management.

In this extended follow-up of the PALOMA-2 trial, no significant differences in overall quality of life were observed between first-line treatments for metastatic breast cancer, but palbociclib plus letrozole showed some benefits regarding side-effects and hair loss.

This study found that quality of life, overall survival, and progression-free survival are the most important factors for postmenopausal patients with advanced breast cancer when considering treatment options.

Safe treatments like minoxidil and spironolactone can help manage hair loss in breast cancer patients without increasing cancer risk.

This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.

This paper reviews various causes of alopecia in cancer patients and highlights the importance of understanding these mechanisms for effective management, but reports no new findings.

This review highlights the challenges and management strategies associated with persistent chemotherapy-induced alopecia, detailing the psychosocial impacts, follicular pathobiology, and available treatments such as scalp cooling and minoxidil, ultimately proposing a clinical algorithm to transform it into a preventable and manageable condition.

This review discusses various strategies to mitigate taxane-induced alopecia in cancer treatment, highlighting the potential of low-intensity ultrasound to reverse hair follicle damage by disrupting taxane-stabilized microtubules.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

In this study, researchers presented cases of cellular neurothekeoma in three male family members with early-onset in infancy, suggesting a potential genetic component and inheritance pattern, which deviates from the typical presentation seen mostly in women between 20–30 years.

This study highlights conflicting evidence on the safety and efficacy of nutritional supplements for hair loss in breast cancer patients, emphasizing the need for oncologist management and further research.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This study found that human umbilical cord mesenchymal stem cells (hUCMSCs) promoted hair regeneration in androgenetic alopecia model mice by activating Wnt/β-catenin signaling, enhancing hair follicle stem cell proliferation, and reducing dermal papilla cell apoptosis.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that cyclin-dependent kinase 4/6 inhibitors used for metastatic breast cancer caused alopecia resembling androgenetic alopecia, negatively impacting patients' quality of life, but topical minoxidil showed potential for improvement.

This review discusses the use of CDK4/6 inhibitors with endocrine therapy in treating women with HR+ HER2- advanced breast cancer, but it reports no new clinical findings.

This study concluded that while CDK4/6 inhibitors, used to treat HR+ HER2- metastatic breast cancer, generally did not worsen health-related quality of life, they were associated with increased patient-reported issues like diarrhea and hair loss upset.

This study observed that dalpiciclib is associated with fewer adverse events like diarrhea and hepatotoxicity compared to other CDK4/6 inhibitors, potentially offering better patient-perceived safety and quality of life.

This study found that alopecia induced by CDK4/6 inhibitors in breast cancer patients occurs more quickly and is more resistant to minoxidil treatment compared to endocrine therapy-induced alopecia.

NFATc1 controls hair stem cell activity, affecting hair growth and could be a target for hair loss treatments.

This review examines cell senescence pathways in melanocytes, highlighting the involvement of telomere attrition, the p16/RB pathway, and cAMP signaling in the context of melanoma development, but reports no new findings.